GSK PLC (LSE:GSK, NYSE:GSK) has secured a legal victory in the ongoing Zantac (ranitidine) litigation, with the Florida State court in the US excluding the plaintiffs' expert testimony as unreliable.
Thousands of lawsuits have been filed against the British drugmaker alleging that the Zantac heartburn medication’s active ingredient ranitidine causes cancer.
The court found that expert evidence presented in the Wilson case was unreliable since it failed to meet the ‘Daubert’ test.
Established in the US Supreme Court case Daubert v. Merrell Dow Pharmaceuticals, the Daubert standard provides criteria for evaluating whether expert testimony is admissible under Federal Rule of Evidence 702.
GSK won a similar dismissal in December 2022.
“GSK continues to defend itself vigorously, including against all remaining claims in other jurisdictions,” the company said in a Friday statement.